Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
59.8 EUR | -0.30% |
|
+0.03% | -12.97% |
Jul. 12 | Morgan Stanley Adjusts Henry Schein's Price Target to $60 From $65 | MT |
Jul. 09 | Leerink Partners Adjusts Price Target on Henry Schein to $72 From $77, Maintains Market Perform Rating | MT |
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.77 for the current period. Therefore, the company is undervalued.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.97% | 8.34B | - | ||
+14.29% | 1.41B | - | ||
-5.71% | 1.34B | D | ||
-28.70% | 1.04B | B+ | ||
-33.75% | 705M | - | - | |
-.--% | 623M | - | - | |
+4.78% | 473M | - | ||
+1.02% | 428M | - | - | |
-37.14% | 277M | - | - | |
+3.26% | 223M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HSIC Stock
- HS2 Stock
- Ratings Henry Schein, Inc.